Identify potential cross-hypersensitivity
Drug allergy is common and can complicate drug therapy and optimal drug choice (1,2). Up to 20% of emergency room visits for anaphylaxis are due to drug allergy (3). Cross-hypersensitivities between drugs may be triggered by resemblances in the chemical structure of related or unrelated drugs. This cross-reactivity can cause unexpectable adverse drug reactions.
20%
“Up to 20% of emergency room visits for anaphylaxis are due to drug allergy.”
Clinical solution
Xreactbase improves patient safety by providing risk analysis for cross-hypersensitivities between drugs. It does not only detail consequences of cross-hypersensitivities but also provides comprehensive information on how to avoid or control the associated clinical risks. Cross-hypersensitivities between drugs form a large group of preventable adverse drug reactions, which can be handled with support provided by Xreactbase.
Key characteristics
of Xreactbase
- Evidence-based knowledge on cross-hypersensitivities of drugs that cause preventable drug harm
- Risk analysis given for each substance level
- Information on the frequency of cross-hypersensitivities
- Descriptions of clinical presentations of cross-hypersensitivities
- Consideration of active substance formulations and drug administration routes
- Recommendations on clinical actions to safeguard against adverse drug reactions
- Inclusion of prescription and over-the-counter drugs
Classification methodology
Classification and recommendations in Xreactbase
The clinical significance of cross-hypersensitivity risk is divided into four categories, coded with a traffic light-like system and letters (A–D), based on clinical evidence on cross-reactivity risk as well as the structural relationships between the substances.
| D | Cross-hypersensitivity is common, and use should be avoided |
| C | Evidence suggests that cross-hypersensitivity may exist, and drug administration should be done with caution or avoided if the previous hypersensitivity has been serious |
| B | Information is limited, or contradictory, and reliable risk assessment cannot be made |
| A | Evidence points to negligible risk of clinically relevant cross-hypersensitivity |
Languages and local drug registries
Medbase content is available in English and more than ten additional languages. To further improve local usability, we accommodate national, local and customer-specific drug product registries, allowing access to information using local drug product names and IDs.
Integration with local electronic health record (EHR) systems is straightforward, enabling smooth and efficient use of regularly updated Medbase drug information across various countries.
Latest information from trusted sources
All information is based on scientific evidence. We refer to published, peer-reviewed research articles from PubMed, a reliable source of biomedical and life sciences literature, as well as regulatory authority approved documents, such as the Summaries of Product Characteristics (SPC) of drugs.
Medbase Knowledgebase is continuously updated to ensure the inclusion of the latest information.
Supporting informed decisions for safe drug use
Enhanced patient safety
Holistic approach to patient’s pharmacotherapy enabling individualised drug treatment.
100% Evidence-based
Fully referenced information with transparency to original sources: documents approved by regulatory authorities and peer-reviewed literature.
Clinical relevance
We provide comprehensive and concise information for safe use of drugs, accessible from one single source.
Digitalised doctor consultation
Designed to support busy clinical practice for safe use of drugs. All information is created and validated by physicians specialised in clinical pharmacology.
Newsroom
Discover our latest updates & customer references
Genetic variability affects outcomes of drug therapy
- Interview
- PROF. MIKKO NIEMI
“Our product development is foresighted”
- Our People
- CPO MARKUS JANSÉN
Vaaka Partners to invest in Medbase
- Interview
- Gaudin C, Ryan D, Demoly P, Tanno LK. Drug allergy in primary care: systematic review to support quality improvement initiative of management and optimization of healthcare pathways. Curr Opin Allergy Clin Immunol. 2023 Aug 1;23(4):263-270.
- Minaldi E, Phillips EJ, Norton A. Immediate and Delayed Hypersensitivity Reactions to Beta-Lactam Antibiotics. Clin Rev Allergy Immunol. 2022 Jun;62(3):449-462.
- Doña I, Torres MJ, Celik G, Phillips E, Tanno LK, Castells M. Changing patterns in the epidemiology of drug allergy. Allergy. 2024 Mar;79(3):613-628.